These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 21037119)

  • 21. Quality of life and depression among HIV-infected patients receiving efavirenz- or protease inhibitor-based therapy in Senegal.
    Poupard M; Ngom Gueye NF; Thiam D; Ndiaye B; Girard PM; Delaporte E; Sow PS; Landman R
    HIV Med; 2007 Mar; 8(2):92-5. PubMed ID: 17352765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.
    Gutiérrez F; Navarro A; Padilla S; Antón R; Masiá M; Borrás J; Martín-Hidalgo A
    Clin Infect Dis; 2005 Dec; 41(11):1648-53. PubMed ID: 16267739
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of concomitant use of montelukast and efavirenz on neuropsychiatric adverse events.
    Ibarra-Barrueta O; Palacios-Zabalza I; Mora-Atorrasagasti O; Mayo-Suarez J
    Ann Pharmacother; 2014 Jan; 48(1):145-8. PubMed ID: 24259633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.
    Neukam K; Mira JA; Ruiz-Morales J; Rivero A; Collado A; Torres-Cornejo A; Merino D; de Los Santos-Gil I; Macías J; González-Serrano M; Camacho A; Parra-García G; Pineda JA;
    J Antimicrob Chemother; 2011 Nov; 66(11):2605-14. PubMed ID: 21903660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.
    Wintergerst U; Hoffmann F; Jansson A; Notheis G; Huss K; Kurowski M; Burger D
    J Antimicrob Chemother; 2008 Jun; 61(6):1336-9. PubMed ID: 18343800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from efavirenz to nevirapine.
    Gelinck LB; Burger DM
    Clin Infect Dis; 2010 Aug; 51(3):365; author reply 365-6. PubMed ID: 20578877
    [No Abstract]   [Full Text] [Related]  

  • 27. Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
    Echeverría P; Negredo E; Carosi G; Gálvez J; Gómez JL; Ocampo A; Portilla J; Prieto A; López JC; Rubio R; Mariño A; Pedrol E; Viladés C; del Arco A; Moreno A; Bravo I; López-Blazquez R; Pérez-Alvarez N; Clotet B
    Antiviral Res; 2010 Feb; 85(2):403-8. PubMed ID: 19941906
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efavirenz + emtricitabine + tenofovir: new combination. HIV infection: do not modify ongoing therapy just to use one less tablet. Better adherence than with separate dosing has not been demonstrated, while reduced efficacy is plausible.
    Prescrire Int; 2009 Jun; 18(101):105. PubMed ID: 19637416
    [No Abstract]   [Full Text] [Related]  

  • 30. Raltegravir as effective as efavirenz in 144-week data.
    AIDS Patient Care STDS; 2009 Aug; 23(8):679-80. PubMed ID: 19694035
    [No Abstract]   [Full Text] [Related]  

  • 31. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort.
    Domingo P; Suárez-Lozano I; Torres F; Teira R; Lopez-Aldeguer J; Vidal F; Muñoz A; Viciana P; Lozano F; Vergara A; Roca B; García Alcalde ML; Cosín J; Terrón A; Galindo MJ; Geijo P; Ribera E; Gonzalez J; Sanchez T; Lacalle JR; Garrido M
    J Antimicrob Chemother; 2008 Jun; 61(6):1348-58. PubMed ID: 18356150
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efavirenz treatment and false-positive results in benzodiazepine screening tests.
    Blank A; Hellstern V; Schuster D; Hartmann M; Matthée AK; Burhenne J; Haefeli WE; Mikus G
    Clin Infect Dis; 2009 Jun; 48(12):1787-9. PubMed ID: 19432553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial.
    Read TR; Carey D; Mallon P; Mijch A; Goodall R; Hudson F; Wand H; Emery S
    AIDS; 2009 Oct; 23(16):2222-3. PubMed ID: 19773634
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does pregnancy affect the pharmacokinetics of efavirenz?
    Hill A; Ford N; Boffito M; Pozniak A; Cressey TR
    AIDS; 2014 Jun; 28(10):1542-3. PubMed ID: 24896806
    [No Abstract]   [Full Text] [Related]  

  • 35. [The use of the non-nucleoside reverse transcriptase inhibitors nevirapine and efavirenz in the treatment of patients with a chronic HIV-I infection].
    van Leth F; Lange JM
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1719-22. PubMed ID: 16924943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Status epilepticus resulting from severe efavirenz toxicity in an HIV-infected patient.
    Nijhawan AE; Zachary KC; Kwara A; Venna N
    AIDS Read; 2008 Jul; 18(7):386-8, C3. PubMed ID: 18655316
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Tolerance study of a triple first-line antiretroviral combination zidovudine, lamivudine and efavirenz in Dakar, Senegal].
    Seydi M; Diop SA; Dieng AB; Tekpa G; Soumaré M; Diouf A; Niang Kh; Lakh A; Ndiaye I; Fall MB; Diop BM; Sow A; Sow PS
    Bull Soc Pathol Exot; 2009 May; 102(2):99-100. PubMed ID: 19583031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maraviroc reduces viral load in naive patients at 48 weeks.
    AIDS Patient Care STDS; 2007 Sep; 21(9):703-4. PubMed ID: 17941136
    [No Abstract]   [Full Text] [Related]  

  • 39. Neuropsychiatric complications of antiretroviral therapy.
    Cespedes MS; Aberg JA
    Drug Saf; 2006; 29(10):865-74. PubMed ID: 16970510
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transition modeling of neuropsychiatric impairment in HIV.
    Bisaso KR; Mukonzo JK; Ette EI
    Comput Biol Med; 2016 Jun; 73():141-6. PubMed ID: 27107677
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.